Hang W, Xu Z X, Zhang Q, Lu X, Liu G
Department of Otorhinolaryngology Head and Neck Surgery, Tianjin HuanHu Hospital, Tianjin 300350, China.
Division of Hematology and Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jan 7;52(1):67-70. doi: 10.3760/cma.j.issn.1673-0860.2017.01.015.
Immune checkpoint inhibitor therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, improves the life quality of cancer patients and has joined the ranks of surgery, radiation, and chemotherapy to become a major choice for cancer therapy. Over the past few years, multiple exciting results have been obtained on checkpoint inhibitor therapy in advanced head and neck cancer. However, questions such as patient selection and biomarkers for assessing the therapy are largely unsolved. Herein, we briefly review recent findings in checkpoint inhibitor therapy for advanced head and neck cancer. We will also discuss possible mechanism, safety, combination therapy, and side effects for the therapy. Checkpoint inhibitor therapy has led to important clinical advances and will provide a new weapon against cancer.
免疫检查点抑制剂疗法通过靶向T细胞中的调节通路来增强抗肿瘤免疫反应，提高了癌症患者的生活质量，并已跻身手术、放疗和化疗之列，成为癌症治疗的主要选择。在过去几年中，晚期头颈癌的检查点抑制剂疗法取得了多项令人振奋的成果。然而，诸如患者选择和评估该疗法的生物标志物等问题在很大程度上仍未得到解决。在此，我们简要回顾晚期头颈癌检查点抑制剂疗法的最新研究结果。我们还将讨论该疗法可能的机制、安全性、联合疗法及副作用。检查点抑制剂疗法已带来重要的临床进展，并将为对抗癌症提供一种新武器。
